Market Flux Event
Karyopharm Therapeutics Files for Bankruptcy and Plans Merger with Ayrmid Ltd
Read this in the Market Flux appKaryopharm Therapeutics (Nasdaq: KPTI) filed for bankruptcy on November 2, 2026 and announced a planned merger with Ayrmid Ltd, a move the company described as intended to strengthen Karyopharm for the future. Shares fell 68.2% in pre-market trading following the announcement.
The bankruptcy filing came after months of deteriorating liquidity. As of June 30, 2026, the company held approximately $65.1 million in cash and investments but had warned that funds would only last into September 2026. Karyopharm missed a $15.8 million principal payment under its senior secured term loan on September 10, 2026, and entered a forbearance agreement with lenders that was subsequently extended to November 1, 2026, one day before the bankruptcy filing.
Karyopharm is a Newton, Massachusetts-based commercial-stage pharmaceutical company focused on cancer therapies that target nuclear export pathways. Its key asset is selinexor, marketed under the brand name Xpovio. The merger with Ayrmid Ltd is positioned as a restructuring path to preserve the company's operations and pipeline.
© AI-generated summary is provided by Market Flux